Cargando…
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
BACKGROUND: Hematologic toxicities, including coagulopathy, endothelial activation, and cytopenias, with CD19-targeted chimeric antigen receptor (CAR) T-cell therapies correlate with cytokine release syndrome (CRS) and neurotoxicity severity, but little is known about the extended toxicity profiles...
Autores principales: | Jess, Jennifer, Yates, Bonnie, Dulau-Florea, Alina, Parker, Kevin, Inglefield, Jon, Lichtenstein, Dan, Schischlik, Fiorella, Ongkeko, Martin, Wang, Yanyu, Shahani, Shilpa, Cullinane, Ann, Smith, Hannah, Kane, Eli, Little, Lauren, Chen, Dong, Fry, Terry J, Shalabi, Haneen, Wang, Hao-Wei, Satpathy, Ansuman, Lozier, Jay, Shah, Nirali N |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10277551/ https://www.ncbi.nlm.nih.gov/pubmed/37295816 http://dx.doi.org/10.1136/jitc-2022-005898 |
Ejemplares similares
-
Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy
por: Amidi, Yalda, et al.
Publicado: (2022) -
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
por: Wehrli, Marc, et al.
Publicado: (2022) -
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
por: Qin, Haiying, et al.
Publicado: (2021) -
CAR T-cell detection scoping review: an essential biomarker in critical need of standardization
por: Turicek, David P, et al.
Publicado: (2023) -
Bone marrow MSC from pediatric patients with B-ALL highly immunosuppress T-cell responses but do not compromise CD19-CAR T-cell activity
por: Zanetti, Samanta Romina, et al.
Publicado: (2020)